JMP Securities upgraded Sabra Health Care (SBRA) to Outperform from Market Perform with a $20 price target The firm expects “multiple tailwinds to result in outsized returns” for the stock.

I created Within This Party as a graduation project in 2022. The world was not much better back then, than it is today. Although perhaps on the surface, it was brighter. But there was darkness in ...

On Dec. 5, Mizuho analyst Vikram Malhotra downgraded the rating for Sabra Health Care REIT from Outperform to Neutral and maintained the price target of $20. On Oct. 31, Sabra Health Care REIT ...